Form 4: Tarsus CEO Sells $300K in Stock Under 10b5-1 Plan

Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of common stock for $50 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc. (TARS), reported a sale of common stock.
• The transaction involved the disposition of 6,000 shares of Tarsus Pharmaceuticals common stock.
• The shares were sold at a price of $50 per share.
• The total value of the shares sold was $300,000.
• The sale was executed on August 11, 2025, as part of an automatic sale pursuant to a Rule 10b5-1 trading plan.
• The Rule 10b5-1 trading plan was adopted by Mr. Azamian on December 12, 2024.
• Following the reported transaction, Mr. Azamian directly beneficially owns 818,106 shares of common stock.
• Additionally, Mr. Azamian indirectly beneficially owns 53,635 shares through the Bobak Azamian Living Trust, for which he is the trustee with voting and dispositive power.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale reduces direct ownership, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic timing, indicating a planned liquidity event rather than a reaction to negative company news.

Negatives

• The sale reduces the direct equity stake of the President/CEO and Board Chair in the company.

Risks

• Despite being executed under a pre-arranged 10b5-1 plan, some investors may perceive insider selling as a negative signal regarding management's confidence in the company's near-term prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of an insider stock transaction. In the pharmaceutical and biotech industry, insider transactions are closely watched for signals about company prospects, though sales under pre-arranged 10b5-1 plans are generally viewed as less indicative of management's immediate sentiment compared to open market sales.

Related Party Transactions

• The indirect beneficial ownership of 53,635 shares is held by the Bobak Azamian Living Trust, established April 16, 2018, for which the Reporting Person is the trustee.

Stakeholder Impact

• Shareholders may observe a slight reduction in the CEO's direct equity alignment, though the pre-planned nature of the sale lessens its perceived impact.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this routine insider transaction.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled sale by the CEO under a 10b5-1 plan, which is a routine liquidity event and not typically indicative of a change in the company's fundamental outlook. While it reduces the CEO's direct stake, it does not suggest a need to alter an existing investment thesis based solely on this transaction. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position and consider broader company performance and market conditions.

Keywords

Tarsus Pharmaceuticals, TARS, Bobak Azamian, Insider Sale, Form 4, 10b5-1 Plan, CEO Stock Sale, Pharmaceuticals, Biotech